vs
Five Point Holdings, LLC（FPH）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是Five Point Holdings, LLC的1.4倍（$19.6M vs $13.6M），Five Point Holdings, LLC净利率更高（-16.4% vs -177.4%，领先161.0%），Five Point Holdings, LLC同比增速更快（3.2% vs -11.5%），过去两年STANDARD BIOTOOLS INC.的营收复合增速更高（-12.2% vs -48.5%）
Five Point Holdings, LLC是美国头部房地产开发企业，主要在加利福尼亚州高需求市场打造大型总体规划综合社区，项目融合住宅、办公、零售、公共配套与休闲设施，为当地居民构建活力、可持续的宜居宜业环境。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
FPH vs LAB — 直观对比
营收规模更大
LAB
是对方的1.4倍
$13.6M
营收增速更快
FPH
高出14.7%
-11.5%
净利率更高
FPH
高出161.0%
-177.4%
两年增速更快
LAB
近两年复合增速
-48.5%
损益表 — Q1 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $13.6M | $19.6M |
| 净利润 | $-2.2M | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | -43.5% | -168.5% |
| 净利率 | -16.4% | -177.4% |
| 营收同比 | 3.2% | -11.5% |
| 净利润同比 | -109.6% | -28.8% |
| 每股收益（稀释后） | — | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FPHLAB
| Q1 26 | $13.6M | — | ||
| Q4 25 | $75.9M | — | ||
| Q3 25 | $13.5M | $19.6M | ||
| Q2 25 | $7.5M | $21.8M | ||
| Q1 25 | $13.2M | $40.8M | ||
| Q4 24 | $159.8M | — | ||
| Q3 24 | $17.0M | $22.1M | ||
| Q2 24 | $51.2M | $22.5M |
净利润FPHLAB
| Q1 26 | $-2.2M | — | ||
| Q4 25 | $58.7M | — | ||
| Q3 25 | $21.1M | $-34.7M | ||
| Q2 25 | $3.3M | $-33.5M | ||
| Q1 25 | $23.3M | $-26.0M | ||
| Q4 24 | $121.0M | — | ||
| Q3 24 | $4.8M | $-26.9M | ||
| Q2 24 | $14.7M | $-45.7M |
毛利率FPHLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% |
营业利润率FPHLAB
| Q1 26 | -43.5% | — | ||
| Q4 25 | 89.0% | — | ||
| Q3 25 | — | -168.5% | ||
| Q2 25 | — | -118.1% | ||
| Q1 25 | — | -80.8% | ||
| Q4 24 | 87.5% | — | ||
| Q3 24 | 83.6% | -120.9% | ||
| Q2 24 | 86.1% | -134.5% |
净利率FPHLAB
| Q1 26 | -16.4% | — | ||
| Q4 25 | 77.3% | — | ||
| Q3 25 | 156.2% | -177.4% | ||
| Q2 25 | 44.4% | -153.7% | ||
| Q1 25 | 177.0% | -63.8% | ||
| Q4 24 | 75.7% | — | ||
| Q3 24 | 28.0% | -122.0% | ||
| Q2 24 | 28.8% | -203.3% |
每股收益（稀释后）FPHLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.09 | ||
| Q2 25 | — | $-0.09 | ||
| Q1 25 | — | $-0.07 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.07 | ||
| Q2 24 | — | $-0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $332.6M | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.3B | $399.7M |
| 总资产 | $3.2B | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FPHLAB
| Q1 26 | $332.6M | — | ||
| Q4 25 | $425.5M | — | ||
| Q3 25 | $351.1M | $129.4M | ||
| Q2 25 | $456.6M | $158.6M | ||
| Q1 25 | $528.3M | $150.9M | ||
| Q4 24 | $430.9M | — | ||
| Q3 24 | $224.5M | $210.6M | ||
| Q2 24 | $217.4M | $269.8M |
总债务FPHLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M |
股东权益FPHLAB
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.3B | $399.7M | ||
| Q2 25 | $2.2B | $424.5M | ||
| Q1 25 | $2.2B | $454.6M | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.0B | $489.3M | ||
| Q2 24 | $2.0B | $510.3M |
总资产FPHLAB
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | — | ||
| Q3 25 | $3.2B | $539.6M | ||
| Q2 25 | $3.2B | $557.0M | ||
| Q1 25 | $3.2B | $579.6M | ||
| Q4 24 | $3.1B | — | ||
| Q3 24 | $2.9B | $681.5M | ||
| Q2 24 | $2.9B | $708.7M |
负债/权益比FPHLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-44.5M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-23.1M |
| 自由现金流率自由现金流/营收 | — | -118.1% |
| 资本支出强度资本支出/营收 | 0.0% | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-111.1M |
8季度趋势，按日历期对齐
经营现金流FPHLAB
| Q1 26 | $-44.5M | — | ||
| Q4 25 | $105.2M | — | ||
| Q3 25 | $40.4M | $-22.2M | ||
| Q2 25 | $-71.6M | $-20.7M | ||
| Q1 25 | $56.7M | $-30.3M | ||
| Q4 24 | $116.0M | — | ||
| Q3 24 | $-18.0M | $-27.9M | ||
| Q2 24 | $-23.2M | $-39.0M |
自由现金流FPHLAB
| Q1 26 | — | — | ||
| Q4 25 | $105.0M | — | ||
| Q3 25 | — | $-23.1M | ||
| Q2 25 | $-71.7M | $-22.6M | ||
| Q1 25 | $56.7M | $-35.3M | ||
| Q4 24 | $115.2M | — | ||
| Q3 24 | $-18.2M | $-30.1M | ||
| Q2 24 | $-23.6M | $-41.0M |
自由现金流率FPHLAB
| Q1 26 | — | — | ||
| Q4 25 | 138.4% | — | ||
| Q3 25 | — | -118.1% | ||
| Q2 25 | -959.3% | -103.6% | ||
| Q1 25 | 430.9% | -86.6% | ||
| Q4 24 | 72.1% | — | ||
| Q3 24 | -106.9% | -136.4% | ||
| Q2 24 | -46.1% | -182.2% |
资本支出强度FPHLAB
| Q1 26 | 0.0% | — | ||
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.0% | 4.5% | ||
| Q2 25 | 0.8% | 8.7% | ||
| Q1 25 | 0.3% | 12.4% | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 1.3% | 10.2% | ||
| Q2 24 | 0.7% | 8.6% |
现金转化率FPHLAB
| Q1 26 | — | — | ||
| Q4 25 | 1.79× | — | ||
| Q3 25 | 1.92× | — | ||
| Q2 25 | -21.58× | — | ||
| Q1 25 | 2.44× | — | ||
| Q4 24 | 0.96× | — | ||
| Q3 24 | -3.77× | — | ||
| Q2 24 | -1.58× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FPH
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
